monterey bio (“mtryu”) is a specialty purpose acquisition company (spac) with the goal of effecting a merger, asset acquisition, or similar business combination with business targets that are developing or enabling development of pre-commercial therapeutic candidates across a broad array of therapeutic areas, with an initial focus on oncology and immunology.